Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2023 Amgen Inc. (Exact name of registrant as specified in its charter)   Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Amgen Center Drive Thousand Oaks California   91320-1799 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (805) 447-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   AMGN   The Nasdaq Stock Market LLC 2.000% Senior Notes due 2026   AMGN26   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting on May 19, 2023. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows: Item 1 - Election of Directors Each of the following 13 nominees for director were elected to serve a one-year term expiring at the Company’s 2024 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.   Name    Votes For    Votes Against    Abstain    Broker Non- Votes Dr. Wanda M. Austin    394,173,521    3,600,031    713,436    64,052,659 Mr. Robert A. Bradway    370,844,134    24,470,758    3,172,096    64,052,659 Dr. Michael V. Drake    393,354,813    4,340,821    791,354    64,052,659 Dr. Brian J. Druker    394,385,167    3,320,183    781,638    64,052,659 Mr. Robert A. Eckert    366,786,098    30,895,580    805,310    64,052,659 Mr. Greg C. Garland    348,891,130    48,785,661    810,197    64,052,659 Mr. Charles M. Holley, Jr.    375,952,849    21,719,176    814,963    64,052,659 Dr. S. Omar Ishrak    394,074,365    3,631,310    781,313    64,052,659 Dr. Tyler Jacks    388,385,762    9,306,550    794,676    64,052,659 Ms. Ellen J. Kullman    382,005,978    15,755,078    725,932    64,052,659 Ms. Amy E. Miles    379,723,549    18,027,013    736,426    64,052,659 Dr. Ronald D. Sugar    361,610,515    36,064,512    811,961    64,052,659 Dr. R. Sanders Williams    380,631,476    17,063,281    792,231    64,052,659 Item 2 - Advisory Vote on the Frequency of Future Stockholder Advisory Votes to Approve Executive Compensation One year was selected for the advisory vote on the frequency of future stockholder advisory votes to approve executive compensation based upon the following votes:   One Year:   390,912,836 Two Years:   888,684 Three Years:   5,869,436 Abstain:   816,032 Broker Non-Votes:   64,052,659 Consistent with our Board of Directors’ recommendation in our 2023 Proxy Statement and the vote of our stockholders, our Board of Directors has determined that the stockholder advisory vote on executive compensation will occur on an annual basis (every “one year”). Item 3 - Advisory Vote to Approve Our Executive Compensation The advisory vote to approve our executive compensation was approved.   For:   371,994,642 Against:   23,910,086 Abstain:   2,582,260 Broker Non-Votes:   64,052,659 Item 4 - Ratification of Selection of Independent Registered Public Accountants Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2023. No Broker Non-Votes resulted from the vote on this proposal.   For:   438,448,567 Against:   23,252,562 Abstain:   838,518 No other matters were submitted for stockholder action. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       AMGEN INC. Date: May 22, 2023   By:     /s/ Jonathan P. Graham           Name:   Jonathan P. Graham     Title:   Executive Vice President and General Counsel and Secretary